Bardazid ApS has so far been supported by public and private investors. The team behind Bardazid ApS has completed a pallet of proof-of-concept studies on various microorganisms, among others with help from the Department of Microbiology at Aarhus University Hospital, Danish Technological Institute,  Statens Serum Institut, Denmarkt, Dr. Brill + Partner GmbH, Institut für Hygiene und Mikrobiologie, Germany and  Aix-Marseille University, Dept. of Infectious Diseases Crisis Unit and Viral Respiratory Infections Laboratory, France. The studies show that Bardazid Surface^TM  has a unique effect against resistant e.g.:

Fungi :

Aspergillus fumigatus TR 34/L98H

Asp. fumigatusTR46

Fusarium Proliferatum

C. auris

Candida Albicans

Scedoporium

Bacteria:

E. Coli

MRSA resistent (CC’i’)

Staphylococcus aureus

Pseudomonas aeruginosa

Enerococcus hirae

Vira:

SARS-CoV-2 (COVID-19)

Bardazid Surface^TM  is a patented technology, classified as a Class I medical device under the Medical Device Directive (EU) 93/42/EEC.

Bardazid Aps is actively looking for collaboration partners in the manufacturing and commercialization phases.